Expand all sections

Ertugliflozin (L-pyroglutamic acid) / sitagliptin (phosphate monohydrate)

Extended indication Diabetes mellitus type 2
Therapeutic value No judgement

Product

Active substance Ertugliflozin (L-pyroglutamic acid) / sitagliptin (phosphate monohydrate)
Domain Metabolism and Endocrinology
Main indication Diabetes
Extended indication Diabetes mellitus type 2
Manufacturer MSD
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)
Additional remarks Samenwerking tussen MSD en Pfizer, MSD is de registratiehouder.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date May 2017
Expected Registration April 2018
Orphan drug No

Therapeutic value

Therapeutic value No judgement
Substantiation Voor ertugliflozin/sitagliptin (een dpp-iv remmer) isgeen meerwaarde te verwachten tov de momenteel al op de markt zijnde combinatiepreparaten van een SGLT2 remmer met een dpp-iv remmer.
Duration of treatment Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.